详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study.

138| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangdong Province. [2]Cancer Center of Sun Yat-Sen University, Guangdong Province. [3]Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing. [4]Hangzhou First People's Hospital, Zhejiang Province. [5]Lung Tumor Clinical Medicine Center, Shanghai Chest Hospital, Shanghai. [6]Department of Pulmonary Medicine, Zhongshan Hospital Affiliated with Fudan University, Shanghai. [7]Department of Medical Oncology, Tumor Hospital of Harbin Medical University, Helongjiang Province. [8]Tianjin Tumor Hospital, Tianjin. [9]Department of Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Sichuan Province. [10]Tongji Medical College, Huazhong University of Science and Technology, Hubei Province. [11]Nanjing Eight One Hospital, Jiangsu Province. [12]Beijing Lung Cancer Center, Capital Medical University, Beijing. [13]Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, PR China

出处：

DOI：

ISSN：

摘要：

This study is to analyze the data of Chinese subpopulation in the Tarceva Lung Cancer Survival Treatment Study (TRUST-China) which was a global Phase IV study designed to provide erlotinib to previously treated patients with Stage IIIB/IV non-small cell lung cancer. Patients with pathologically confirmed, unresectable Stage IIIB/IV non-small cell lung cancer who were previously failed on or unsuitable for chemotherapy or radiotherapy were given erlotinib (150 mg/day, oral) until disease progression, intolerable toxicity or death. Efficacy and toxicity of the agent were evaluated. In total, 519 patients Chinese patients were analyzed. The TRUST-China had similar baseline characteristics to TRUST-Global except the greater percentage of adenocarcinoma and non-smoker cases. The response rate and disease control rate were 24.7 and 75.3%, respectively. Median progression-free survival and overall survival were 6.4 and 15.4 months in the general Chinese population in the TRUST, and 10.2 and 18.9 months in non-smokers with adenocarcinoma (n = 254). Median progression-free survival and overall survival were significantly longer in non-smokers with adenocarcinoma than those in other groups (P ≤ 0.0001 and P ≤ 0.0001, respectively). Eastern Cooperative Oncology Group Performance Status (≥ 2 vs. ≤ 1, hazard ratio = 1.746, P < 0.0001) and histology (squamous cell carcinoma vs. adenocarcinoma, hazard ratio = 1.595, P = 0.0008) were independent risk factors that affected survival according to Cox regression multivariate analysis. We confirmed the efficacy and safety of erlotinib in Chinese patients. Non-smoking patients with adenocarcinoma histology had the best clinical benefits. (NCT00949910). © The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2015]版：

大类 | 4 区医学

小类 | 4 区肿瘤学

最新[2023]版：

大类 | 4 区医学

小类 | 4 区肿瘤学

JCR分区：

出版当年[2015]版：

Q4 ONCOLOGY

最新[2023]版：

Q3 ONCOLOGY

影响因子： 1.9 最新[2023版] 2.4 最新五年平均 1.889 出版当年[2015版] 2.01 出版当年五年平均 2.016 出版前一年[2014版] 1.905 出版后一年[2016版]

第一作者：

第一作者机构： [1]Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangdong Province.

通讯作者：

通讯机构： [13]Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, PR China [*1]Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, No. 507 Zhengmin Road, Shanghai 200433, PR China.

推荐引用方式(GB/T 7714)：

APA：

MLA：